Agile Therapeutics has a Cash Ratio of 0.11. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Agile Therapeutics's Cash Ratio or its related term are showing as below:
AGRX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 3.8 Max: 33.45
Current: 0.11
During the past 12 years, Agile Therapeutics's highest Cash Ratio was 33.45. The lowest was 0.11. And the median was 3.80.
AGRX's Cash Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.59
vs AGRX: 0.11
Agile Therapeutics Cash Ratio Historical Data
The historical data trend for Agile Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Agile Therapeutics's Cash Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's Cash Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's Cash Ratio falls into.
Agile Therapeutics Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Agile Therapeutics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agile Therapeutics (OTCPK:AGRX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Agile Therapeutics Cash Ratio Related Terms
Thank you for viewing the detailed overview of Agile Therapeutics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your 